Details of the Drug
General Information of Drug (ID: DMQ4L1I)
| Drug Name |
Dansylamide
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Dansylamide; 1431-39-6; 5-(dimethylamino)naphthalene-1-sulfonamide; 5-DIMETHYLAMINO-1-NAPHTHALENESULFONAMIDE; Dansyl amide; 5-Dimethylaminonaphthalene-1-sulfonamide; 5-(DIMETHYLAMINO)-1-NAPHTHALENESULFONAMIDE; TYNBFJJKZPTRKS-UHFFFAOYSA-N; 5-[Dimethylamino]-1-naphthalenesulfonamide; 1-Naphthalenesulfonamide, 5-(dimethylamino)-; 1okl; EINECS 215-854-1; AC1Q3WHH; 5-(Dimethylamino)naphthalene-1-sulphonamide; AC1L22JG; Oprea1_628153; SCHEMBL108421; CHEMBL119489; ZINC56543; BDBM11402; TYNBFJJKZPTRKS-UHFFFAOYSA-; DTXSID70162306
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 250.32 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 2 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


